Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 11/20 | 0.42 |
| ▸ | PLK1 | P53350 | 2/20 | 0.42 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 5/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114821 | 0.89 | LMNA (0.41) | NEK2ELANEP2RY12KDM4ELMNA | |
| SCHEMBL4103192 | 0.87 | ELANE (0.40) | NEK2PLK1NEK1ELANEP2RY12 | |
| SCHEMBL4099858 | 0.86 | ELANE (0.41) | NEK2PLK1NEK1ELANEP2RY12 | |
| SCHEMBL4097530 | 0.86 | ELANE (0.39) | NEK2PLK1NEK1ELANEP2RY12 | |
| SCHEMBL4104971 | 0.85 | ELANE (0.38) | NEK2PLK1NEK1ELANEP2RY12 | |
| SCHEMBL4011186 | 0.82 | P2RY12 (0.44) | NEK2PLK1NEK1ELANEP2RY12 | |
| SCHEMBL4873002 | 0.82 | CYP3A4 (0.45) | P2RY12CYP2C19 | |
| SCHEMBL4097396 | 0.81 | ELANE (0.42) | NEK2PLK1NEK1ELANEP2RY12 | |
| SCHEMBL4097532 | 0.80 | P2RY12 (0.60) | P2RY12CYP2C19 | |
| SCHEMBL4105130 | 0.78 | NEK2 (0.42) | NEK2ELANEP2RY12KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| CN-101263133-A | New pyridine analogues | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| US-20080044570-A1 | Method for Producing a Thin-Film Chalcopyrite Compound | SOLARONIX SA (CH) | 2008-02-21 | — | — | US | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | NEK2 2807/4885PLK1 3122/4885NEK1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.